2018
Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
VESELKA, Josef, Lothar FABER, Morten Kvistholm JENSEN, Robert COOPER, Jaroslav JANUSKA et. al.Základní údaje
Originální název
Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
Autoři
VESELKA, Josef (203 Česká republika, garant), Lothar FABER (276 Německo), Morten Kvistholm JENSEN (208 Dánsko), Robert COOPER (826 Velká Británie a Severní Irsko), Jaroslav JANUSKA (203 Česká republika), Jan KREJČÍ (203 Česká republika, domácí), Thomas BARTEL (784 Spojené arabské emiráty), Maciej DABROWSKI (616 Polsko), Peter Riis HANSEN (208 Dánsko), Vibeke Marie ALMAAS (578 Norsko), Hubert SEGGEWISS (276 Německo), Dieter HORSTKOTTE (276 Německo), Radka ADLOVA (203 Česká republika), Henning BUNDGAARD (208 Dánsko), Jurrien ten BERG (528 Nizozemské království) a Max LIEBREGTS (528 Nizozemské království)
Vydání
Canadian Journal of Cardiology, New York, Elsevier Science Ltd. 2018, 0828-282X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 5.592
Kód RIV
RIV/00216224:14110/18:00105231
Organizační jednotka
Lékařská fakulta
UT WoS
000418674300007
Klíčová slova anglicky
hypertrophic cardiomyopathy
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 9. 2. 2019 22:30, Soňa Böhmová
Anotace
V originále
Background: The current American College of Cardiology Foundation/American Heart Association guidelines on hypertrophic cardiomyopathy state that institutional experience is a key determinant of successful outcomes and lower complication rates of alcohol septal ablation (ASA). The aim of this study was to evaluate the safety and efficacy of ASA according to institutional experience with the procedure. Methods: We retrospectively evaluated 1310 patients with symptomatic obstructive hypertrophic cardiomyopathy who underwent ASA and were divided into 2 groups. The first-50 group consisted of the first consecutive 50 patients treated at each centre, and the over-50 group consisted of patients treated thereafter (patients 51 and above). Results: In the 30-day follow-up, there was a significant difference in the occurrence of major cardiovascular adverse events (21% in the first-50 group vs 12% in the over-50 group; P < 0.01), which was driven by the occurrence of cardiovascular deaths (2.1% vs 0.4%; P = 0.01) and implanted pacemakers (15% vs 9%; P < 0.01). In the long-term follow-up (5.5 +/- 4.1 years), the first-50 group was associated with a significantly higher occurrence of major adverse events (P < 0.01) and higher cardiovascular mortality (P < 0.01). Also, patients in the first-50 group were more likely to self-report dyspnea of New York Heart Association class III/IV (16% vs 10%), to have a left ventricular outflow gradient > 30 mm Hg (16% vs 10%) at the last clinical check-up (P < 0.01 for both), and a probability of repeated septal reduction therapy (P = 0.03). Conclusions: An institutional experience of > 50 ASA procedures was associated with a lower occurrence of ASA complications, better cardiovascular survival, better hemodynamic and clinical effect, and less need for repeated septal reduction therapy.